Alto Neuroscience presents Phase 2a data for ALTO-207 in MDD

Alto Neuroscience (ANRO) announced the presentation of data from a randomized, single-blind, placebo-controlled Phase 2a trial of ALTO-207 in patients with Major Depressive Disorder, MDD. The data were presented in a poster session at the 2026 Annual Meeting of the Society of Biological Psychiatry, SOBP. Presentation Highlights; Phase 2a Trial Design and Results: Titration: Participants reached a mean pramipexole dose of 4.1 mg within 8 days; 60% tolerated the maximum 5 mg dose by day 12. MADRS: ALTO-207 showed a statistically significant reduction in depressive symptoms versus placebo at Week 6 and Week 8. CGI-S: A statistically significant reduction in illness severity was observed at Week 6 and Week 8. Tolerability: No participants in the ALTO-207 arm discontinued due to adverse events during the maintenance phase. Treatment-related nausea was reported in 15% of ALTO-207 participants during the post-titration maintenance period. The titration schedule being employed in the ongoing Phase 2b trial has been modified with the goal of further improving tolerability.